Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes.

Saved in:

Bibliographic Details
Title:	Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes.
Authors:	Chow E; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.; Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong, China.; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China., Wang K; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.; Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong, China.; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China., Lim CKP; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.; Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong, China., Tsoi STF; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.; Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong, China., Fan B; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.; Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong, China., Poon E; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China., Luk AOY; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.; Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong, China.; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China., Ma RCW; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.; Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong, China., Ferrannini E; Institute of Clinical Physiology, National Research Council of Italy (CNR), Pisa, Italy., Mari A; Institute of Neuroscience, National Research Council of Italy (CNR), Padua, Italy., Chen L; Hua Medicine, Shanghai, China., Chan JCN; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.; Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong, China.
Source:	Diabetes [Diabetes] 2023 Feb 01; Vol. 72 (2), pp. 299-308.
Publication Type:	Randomized Controlled Trial; Journal Article
Journal Info:	Publisher: American Diabetes Association Country of Publication: United States NLM ID: 0372763 Publication Model: Print Cited Medium: Internet ISSN: 1939-327X (Electronic) Linking ISSN: 00121797 NLM ISO Abbreviation: Diabetes Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1939-327X
DOI:	10.2337/db22-0708